Jeuveau (Daewoong Pharmaceutical)Daewoong Pharmaceutical said Thursday its US partner Evolus' botulinum toxin treatment program using its Nabota, or Jeuveau, has secured over 600,000 subscribers in the US.Daewoong added that 96 percent of patients enrolled in the botulinum toxin program have returned for a second injection, promising Nabota's further growth in the US market.Evolus is a California-based performance beauty company that is responsible for sales of Daewoong Pharmaceutical's Nabota in the US market.

https://n.news.naver.com/mnews/article/044/0000248131?sid=104

#naver